nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Iron deficiency—Octreotide—thymus cancer	0.142	0.19	CcSEcCtD
Everolimus—Basal cell carcinoma—Octreotide—thymus cancer	0.0288	0.0385	CcSEcCtD
Everolimus—Pruritus generalised—Octreotide—thymus cancer	0.0203	0.0272	CcSEcCtD
Everolimus—MTOR—neck—thymus cancer	0.0197	0.0946	CbGeAlD
Everolimus—Osteonecrosis—Octreotide—thymus cancer	0.0182	0.0244	CcSEcCtD
Everolimus—FKBP1A—neck—thymus cancer	0.0178	0.0851	CbGeAlD
Everolimus—MTOR—hematopoietic system—thymus cancer	0.0147	0.0704	CbGeAlD
Everolimus—Pancreatitis acute—Octreotide—thymus cancer	0.0147	0.0197	CcSEcCtD
Everolimus—MTOR—epithelium—thymus cancer	0.0134	0.0644	CbGeAlD
Everolimus—FKBP1A—hematopoietic system—thymus cancer	0.0132	0.0633	CbGeAlD
Everolimus—FKBP1A—epithelium—thymus cancer	0.0121	0.0579	CbGeAlD
Everolimus—Cholecystitis—Octreotide—thymus cancer	0.0118	0.0158	CcSEcCtD
Everolimus—Haemorrhoids—Octreotide—thymus cancer	0.0115	0.0154	CcSEcCtD
Everolimus—Transaminases increased—Octreotide—thymus cancer	0.0111	0.0149	CcSEcCtD
Everolimus—Cholelithiasis—Octreotide—thymus cancer	0.0109	0.0146	CcSEcCtD
Everolimus—MTOR—pituitary gland—thymus cancer	0.0109	0.0522	CbGeAlD
Everolimus—Haematoma—Octreotide—thymus cancer	0.0108	0.0144	CcSEcCtD
Everolimus—Nail disorder—Octreotide—thymus cancer	0.0105	0.014	CcSEcCtD
Everolimus—MTOR—lymphoid tissue—thymus cancer	0.0103	0.0496	CbGeAlD
Everolimus—FKBP1A—cardiac atrium—thymus cancer	0.01	0.0481	CbGeAlD
Everolimus—FKBP1A—pituitary gland—thymus cancer	0.0098	0.047	CbGeAlD
Everolimus—Neuralgia—Octreotide—thymus cancer	0.00976	0.0131	CcSEcCtD
Everolimus—Metrorrhagia—Octreotide—thymus cancer	0.00949	0.0127	CcSEcCtD
Everolimus—MTOR—bone marrow—thymus cancer	0.00942	0.0451	CbGeAlD
Everolimus—MTOR—thyroid gland—thymus cancer	0.0094	0.045	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—thymus cancer	0.0093	0.0446	CbGeAlD
Everolimus—Herpes zoster—Octreotide—thymus cancer	0.00901	0.0121	CcSEcCtD
Everolimus—Otitis media—Octreotide—thymus cancer	0.00871	0.0117	CcSEcCtD
Everolimus—Coagulopathy—Octreotide—thymus cancer	0.00871	0.0117	CcSEcCtD
Everolimus—MTOR—lung—thymus cancer	0.00853	0.0409	CbGeAlD
Everolimus—FKBP1A—bone marrow—thymus cancer	0.00847	0.0406	CbGeAlD
Everolimus—FKBP1A—thyroid gland—thymus cancer	0.00845	0.0405	CbGeAlD
Everolimus—Endocrine disorder—Octreotide—thymus cancer	0.00818	0.0109	CcSEcCtD
Everolimus—Acne—Octreotide—thymus cancer	0.00806	0.0108	CcSEcCtD
Everolimus—Amenorrhoea—Octreotide—thymus cancer	0.00772	0.0103	CcSEcCtD
Everolimus—FKBP1A—lung—thymus cancer	0.00768	0.0368	CbGeAlD
Everolimus—Viral infection—Octreotide—thymus cancer	0.00751	0.01	CcSEcCtD
Everolimus—Oropharyngeal pain—Octreotide—thymus cancer	0.00746	0.00998	CcSEcCtD
Everolimus—Cellulitis—Octreotide—thymus cancer	0.00746	0.00998	CcSEcCtD
Everolimus—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00678	0.00907	CcSEcCtD
Everolimus—Hyperkalaemia—Octreotide—thymus cancer	0.00666	0.00892	CcSEcCtD
Everolimus—Wheezing—Octreotide—thymus cancer	0.00659	0.00881	CcSEcCtD
Everolimus—Candida infection—Octreotide—thymus cancer	0.00647	0.00866	CcSEcCtD
Everolimus—Bladder pain—Octreotide—thymus cancer	0.00613	0.0082	CcSEcCtD
Everolimus—Mouth ulceration—Octreotide—thymus cancer	0.00613	0.0082	CcSEcCtD
Everolimus—Urine output increased—Octreotide—thymus cancer	0.00613	0.0082	CcSEcCtD
Everolimus—MTOR—lymph node—thymus cancer	0.00584	0.028	CbGeAlD
Everolimus—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00566	0.00757	CcSEcCtD
Everolimus—Diabetes mellitus—Octreotide—thymus cancer	0.00566	0.00757	CcSEcCtD
Everolimus—Polyuria—Octreotide—thymus cancer	0.00561	0.0075	CcSEcCtD
Everolimus—Gastroenteritis—Octreotide—thymus cancer	0.00555	0.00743	CcSEcCtD
Everolimus—Cardiac failure congestive—Octreotide—thymus cancer	0.00543	0.00726	CcSEcCtD
Everolimus—Nasal congestion—Octreotide—thymus cancer	0.0054	0.00723	CcSEcCtD
Everolimus—Hot flush—Octreotide—thymus cancer	0.00526	0.00704	CcSEcCtD
Everolimus—FKBP1A—lymph node—thymus cancer	0.00525	0.0252	CbGeAlD
Everolimus—Menopausal symptoms—Octreotide—thymus cancer	0.00522	0.00698	CcSEcCtD
Everolimus—Hypoglycaemia—Octreotide—thymus cancer	0.00504	0.00675	CcSEcCtD
Everolimus—Pain in extremity—Octreotide—thymus cancer	0.00492	0.00659	CcSEcCtD
Everolimus—Irritability—Octreotide—thymus cancer	0.0047	0.00629	CcSEcCtD
Everolimus—Dehydration—Octreotide—thymus cancer	0.00458	0.00613	CcSEcCtD
Everolimus—Dry skin—Octreotide—thymus cancer	0.00451	0.00604	CcSEcCtD
Everolimus—Abdominal pain upper—Octreotide—thymus cancer	0.0045	0.00602	CcSEcCtD
Everolimus—Nasopharyngitis—Octreotide—thymus cancer	0.0044	0.00589	CcSEcCtD
Everolimus—Gastritis—Octreotide—thymus cancer	0.00436	0.00583	CcSEcCtD
Everolimus—Muscular weakness—Octreotide—thymus cancer	0.00434	0.00581	CcSEcCtD
Everolimus—CYP3A4—hematopoietic system—thymus cancer	0.00432	0.0207	CbGeAlD
Everolimus—Abdominal distension—Octreotide—thymus cancer	0.00428	0.00573	CcSEcCtD
Everolimus—Influenza—Octreotide—thymus cancer	0.00425	0.00569	CcSEcCtD
Everolimus—Bronchospasm—Octreotide—thymus cancer	0.00419	0.0056	CcSEcCtD
Everolimus—Pancreatitis—Octreotide—thymus cancer	0.00417	0.00558	CcSEcCtD
Everolimus—Bronchitis—Octreotide—thymus cancer	0.00409	0.00548	CcSEcCtD
Everolimus—Dysuria—Octreotide—thymus cancer	0.00398	0.00532	CcSEcCtD
Everolimus—Upper respiratory tract infection—Octreotide—thymus cancer	0.00395	0.00529	CcSEcCtD
Everolimus—Pollakiuria—Octreotide—thymus cancer	0.00393	0.00526	CcSEcCtD
Everolimus—Weight decreased—Octreotide—thymus cancer	0.00385	0.00515	CcSEcCtD
Everolimus—Hyperglycaemia—Octreotide—thymus cancer	0.00384	0.00514	CcSEcCtD
Everolimus—Pneumonia—Octreotide—thymus cancer	0.00382	0.00511	CcSEcCtD
Everolimus—Jaundice—Octreotide—thymus cancer	0.0037	0.00495	CcSEcCtD
Everolimus—Urinary tract infection—Octreotide—thymus cancer	0.00369	0.00493	CcSEcCtD
Everolimus—Conjunctivitis—Octreotide—thymus cancer	0.00369	0.00493	CcSEcCtD
Everolimus—Haematuria—Octreotide—thymus cancer	0.00362	0.00484	CcSEcCtD
Everolimus—Hepatobiliary disease—Octreotide—thymus cancer	0.00359	0.0048	CcSEcCtD
Everolimus—Epistaxis—Octreotide—thymus cancer	0.00358	0.00479	CcSEcCtD
Everolimus—Sinusitis—Octreotide—thymus cancer	0.00356	0.00476	CcSEcCtD
Everolimus—Rhinitis—Octreotide—thymus cancer	0.00341	0.00457	CcSEcCtD
Everolimus—Hepatitis—Octreotide—thymus cancer	0.00341	0.00456	CcSEcCtD
Everolimus—Hypoaesthesia—Octreotide—thymus cancer	0.00339	0.00453	CcSEcCtD
Everolimus—Pharyngitis—Octreotide—thymus cancer	0.00338	0.00452	CcSEcCtD
Everolimus—Oedema peripheral—Octreotide—thymus cancer	0.00335	0.00449	CcSEcCtD
Everolimus—Flushing—Octreotide—thymus cancer	0.00316	0.00423	CcSEcCtD
Everolimus—Cardiac disorder—Octreotide—thymus cancer	0.00316	0.00423	CcSEcCtD
Everolimus—Immune system disorder—Octreotide—thymus cancer	0.00308	0.00412	CcSEcCtD
Everolimus—Alopecia—Octreotide—thymus cancer	0.00301	0.00403	CcSEcCtD
Everolimus—Mental disorder—Octreotide—thymus cancer	0.00298	0.00399	CcSEcCtD
Everolimus—Erythema—Octreotide—thymus cancer	0.00296	0.00397	CcSEcCtD
Everolimus—Malnutrition—Octreotide—thymus cancer	0.00296	0.00397	CcSEcCtD
Everolimus—Flatulence—Octreotide—thymus cancer	0.00292	0.00391	CcSEcCtD
Everolimus—Back pain—Octreotide—thymus cancer	0.00287	0.00384	CcSEcCtD
Everolimus—Muscle spasms—Octreotide—thymus cancer	0.00285	0.00381	CcSEcCtD
Everolimus—Vision blurred—Octreotide—thymus cancer	0.00279	0.00374	CcSEcCtD
Everolimus—Tremor—Octreotide—thymus cancer	0.00278	0.00372	CcSEcCtD
Everolimus—Ill-defined disorder—Octreotide—thymus cancer	0.00275	0.00368	CcSEcCtD
Everolimus—Anaemia—Octreotide—thymus cancer	0.00274	0.00367	CcSEcCtD
Everolimus—Agitation—Octreotide—thymus cancer	0.00272	0.00365	CcSEcCtD
Everolimus—Malaise—Octreotide—thymus cancer	0.00267	0.00358	CcSEcCtD
Everolimus—Syncope—Octreotide—thymus cancer	0.00266	0.00356	CcSEcCtD
Everolimus—Palpitations—Octreotide—thymus cancer	0.00262	0.00351	CcSEcCtD
Everolimus—Loss of consciousness—Octreotide—thymus cancer	0.00261	0.00349	CcSEcCtD
Everolimus—Cough—Octreotide—thymus cancer	0.00259	0.00346	CcSEcCtD
Everolimus—Convulsion—Octreotide—thymus cancer	0.00257	0.00344	CcSEcCtD
Everolimus—Hypertension—Octreotide—thymus cancer	0.00256	0.00342	CcSEcCtD
Everolimus—Chest pain—Octreotide—thymus cancer	0.00252	0.00338	CcSEcCtD
Everolimus—Arthralgia—Octreotide—thymus cancer	0.00252	0.00338	CcSEcCtD
Everolimus—Myalgia—Octreotide—thymus cancer	0.00252	0.00338	CcSEcCtD
Everolimus—Anxiety—Octreotide—thymus cancer	0.00252	0.00337	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00251	0.00335	CcSEcCtD
Everolimus—Discomfort—Octreotide—thymus cancer	0.00249	0.00334	CcSEcCtD
Everolimus—Dry mouth—Octreotide—thymus cancer	0.00247	0.0033	CcSEcCtD
Everolimus—Oedema—Octreotide—thymus cancer	0.00242	0.00324	CcSEcCtD
Everolimus—Infection—Octreotide—thymus cancer	0.0024	0.00322	CcSEcCtD
Everolimus—Shock—Octreotide—thymus cancer	0.00238	0.00319	CcSEcCtD
Everolimus—Nervous system disorder—Octreotide—thymus cancer	0.00237	0.00317	CcSEcCtD
Everolimus—Thrombocytopenia—Octreotide—thymus cancer	0.00237	0.00317	CcSEcCtD
Everolimus—Tachycardia—Octreotide—thymus cancer	0.00236	0.00316	CcSEcCtD
Everolimus—Skin disorder—Octreotide—thymus cancer	0.00235	0.00314	CcSEcCtD
Everolimus—Hyperhidrosis—Octreotide—thymus cancer	0.00234	0.00313	CcSEcCtD
Everolimus—Anorexia—Octreotide—thymus cancer	0.00231	0.00309	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Octreotide—thymus cancer	0.0022	0.00295	CcSEcCtD
Everolimus—Insomnia—Octreotide—thymus cancer	0.00219	0.00293	CcSEcCtD
Everolimus—Paraesthesia—Octreotide—thymus cancer	0.00217	0.00291	CcSEcCtD
Everolimus—Dyspnoea—Octreotide—thymus cancer	0.00216	0.00289	CcSEcCtD
Everolimus—Somnolence—Octreotide—thymus cancer	0.00215	0.00288	CcSEcCtD
Everolimus—Dyspepsia—Octreotide—thymus cancer	0.00213	0.00285	CcSEcCtD
Everolimus—Decreased appetite—Octreotide—thymus cancer	0.0021	0.00281	CcSEcCtD
Everolimus—Gastrointestinal disorder—Octreotide—thymus cancer	0.00209	0.0028	CcSEcCtD
Everolimus—Fatigue—Octreotide—thymus cancer	0.00209	0.00279	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—thymus cancer	0.00208	0.0473	CbGpPWpGaD
Everolimus—Pain—Octreotide—thymus cancer	0.00207	0.00277	CcSEcCtD
Everolimus—Constipation—Octreotide—thymus cancer	0.00207	0.00277	CcSEcCtD
Everolimus—Feeling abnormal—Octreotide—thymus cancer	0.00199	0.00267	CcSEcCtD
Everolimus—Gastrointestinal pain—Octreotide—thymus cancer	0.00198	0.00265	CcSEcCtD
Everolimus—Abdominal pain—Octreotide—thymus cancer	0.00191	0.00256	CcSEcCtD
Everolimus—Body temperature increased—Octreotide—thymus cancer	0.00191	0.00256	CcSEcCtD
Everolimus—Hypersensitivity—Octreotide—thymus cancer	0.00178	0.00239	CcSEcCtD
Everolimus—Asthenia—Octreotide—thymus cancer	0.00174	0.00232	CcSEcCtD
Everolimus—Pruritus—Octreotide—thymus cancer	0.00171	0.00229	CcSEcCtD
Everolimus—Diarrhoea—Octreotide—thymus cancer	0.00166	0.00222	CcSEcCtD
Everolimus—Dizziness—Octreotide—thymus cancer	0.0016	0.00214	CcSEcCtD
Everolimus—Vomiting—Octreotide—thymus cancer	0.00154	0.00206	CcSEcCtD
Everolimus—Rash—Octreotide—thymus cancer	0.00153	0.00204	CcSEcCtD
Everolimus—Dermatitis—Octreotide—thymus cancer	0.00152	0.00204	CcSEcCtD
Everolimus—Headache—Octreotide—thymus cancer	0.00152	0.00203	CcSEcCtD
Everolimus—Nausea—Octreotide—thymus cancer	0.00144	0.00192	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—thymus cancer	0.00124	0.0281	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—thymus cancer	0.000963	0.0219	CbGpPWpGaD
Everolimus—FKBP1A—TOR Signaling—AKT1—thymus cancer	0.000949	0.0216	CbGpPWpGaD
Everolimus—MTOR—CD28 dependent PI3K/Akt signaling—AKT1—thymus cancer	0.000822	0.0187	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD4—thymus cancer	0.000711	0.0162	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—thymus cancer	0.000697	0.0158	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL2—thymus cancer	0.000677	0.0154	CbGpPWpGaD
Everolimus—MTOR—FSH signaling pathway—AKT1—thymus cancer	0.000672	0.0153	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL2—thymus cancer	0.000654	0.0149	CbGpPWpGaD
Everolimus—MTOR—VEGFR2 mediated vascular permeability—AKT1—thymus cancer	0.000653	0.0148	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—thymus cancer	0.000643	0.0146	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—KIT—thymus cancer	0.000628	0.0143	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—thymus cancer	0.000618	0.014	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—KIT—thymus cancer	0.000613	0.0139	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—KIT—thymus cancer	0.000608	0.0138	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—thymus cancer	0.000594	0.0135	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—IL2—thymus cancer	0.000592	0.0135	CbGpPWpGaD
Everolimus—MTOR—CD28 co-stimulation—AKT1—thymus cancer	0.000587	0.0133	CbGpPWpGaD
Everolimus—MTOR—Alpha 6 Beta 4 signaling pathway—AKT1—thymus cancer	0.000572	0.013	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—thymus cancer	0.000549	0.0125	CbGpPWpGaD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—AKT1—thymus cancer	0.000546	0.0124	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—thymus cancer	0.000543	0.0123	CbGpPWpGaD
Everolimus—MTOR—TOR Signaling—AKT1—thymus cancer	0.000534	0.0121	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—AKT1—thymus cancer	0.000522	0.0119	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—AKT1—thymus cancer	0.000511	0.0116	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	0.000483	0.011	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—AKT1—thymus cancer	0.000481	0.0109	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KIT—thymus cancer	0.000469	0.0107	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—AKT1—thymus cancer	0.000463	0.0105	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—thymus cancer	0.000457	0.0104	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KIT—thymus cancer	0.000449	0.0102	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KIT—thymus cancer	0.000442	0.01	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—thymus cancer	0.000435	0.00988	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—AKT1—thymus cancer	0.000431	0.0098	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KIT—thymus cancer	0.000422	0.00959	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KIT—thymus cancer	0.00042	0.00955	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KIT—thymus cancer	0.000418	0.0095	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KIT—thymus cancer	0.000416	0.00945	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CYLD—thymus cancer	0.000415	0.00942	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.00041	0.00932	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—thymus cancer	0.000398	0.00904	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—thymus cancer	0.000394	0.00896	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.000391	0.00889	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KIT—thymus cancer	0.000391	0.00889	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KIT—thymus cancer	0.000391	0.00889	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KIT—thymus cancer	0.000388	0.00881	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KIT—thymus cancer	0.000384	0.00873	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KIT—thymus cancer	0.000383	0.0087	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.00038	0.00864	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—thymus cancer	0.00038	0.00864	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—thymus cancer	0.000376	0.00854	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KIT—thymus cancer	0.000362	0.00823	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.000347	0.00788	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—AKT1—thymus cancer	0.000346	0.00785	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—thymus cancer	0.000333	0.00756	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—AKT1—thymus cancer	0.000329	0.00747	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—AKT1—thymus cancer	0.000329	0.00747	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—AKT1—thymus cancer	0.000321	0.00729	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—AKT1—thymus cancer	0.000321	0.00729	CbGpPWpGaD
Everolimus—MTOR—SREBP signalling—AKT1—thymus cancer	0.000317	0.00721	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—AKT1—thymus cancer	0.000317	0.00721	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAML2—thymus cancer	0.000315	0.00716	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—AKT1—thymus cancer	0.000297	0.00674	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000296	0.00672	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thymus cancer	0.000282	0.0064	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—AKT1—thymus cancer	0.000271	0.00616	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000271	0.00616	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—thymus cancer	0.000269	0.0061	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KIT—thymus cancer	0.000267	0.00606	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	0.000266	0.00604	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.00025	0.00568	CbGpPWpGaD
Everolimus—MTOR—Immune System—CYLD—thymus cancer	0.000242	0.00549	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—AKT1—thymus cancer	0.00024	0.00545	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—AKT1—thymus cancer	0.000234	0.00532	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—AKT1—thymus cancer	0.000232	0.00527	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—thymus cancer	0.000231	0.00524	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—thymus cancer	0.000227	0.00515	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	0.000227	0.00515	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thymus cancer	0.000223	0.00508	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAML2—thymus cancer	0.000221	0.00501	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—AKT1—thymus cancer	0.000211	0.00479	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thymus cancer	0.000201	0.00456	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—thymus cancer	0.000194	0.00442	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—thymus cancer	0.000179	0.00407	CbGpPWpGaD
Everolimus—MTOR—Disease—MAML2—thymus cancer	0.000177	0.00402	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—thymus cancer	0.000176	0.004	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thymus cancer	0.000171	0.00389	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thymus cancer	0.00017	0.00385	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—thymus cancer	0.000169	0.00383	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—thymus cancer	0.000162	0.00368	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—thymus cancer	0.000161	0.00366	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	0.00016	0.00364	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—thymus cancer	0.00016	0.00364	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—thymus cancer	0.00016	0.00362	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—thymus cancer	0.000159	0.00361	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000156	0.00355	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KIT—thymus cancer	0.000152	0.00346	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—thymus cancer	0.000149	0.00339	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—thymus cancer	0.000149	0.00339	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.000149	0.00339	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—thymus cancer	0.000148	0.00336	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thymus cancer	0.000147	0.00333	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—thymus cancer	0.000146	0.00332	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KIT—thymus cancer	0.000146	0.00332	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KIT—thymus cancer	0.000145	0.0033	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—thymus cancer	0.000138	0.00314	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	0.000132	0.00301	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—thymus cancer	0.000128	0.00292	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAML2—thymus cancer	0.000124	0.00282	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—thymus cancer	0.000118	0.00268	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—thymus cancer	0.000116	0.00264	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—thymus cancer	0.000112	0.00254	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—thymus cancer	0.000111	0.00253	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—thymus cancer	0.000102	0.00231	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—thymus cancer	0.000102	0.00231	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—thymus cancer	8.86e-05	0.00201	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—thymus cancer	8.18e-05	0.00186	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—thymus cancer	7.16e-05	0.00163	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—thymus cancer	6.77e-05	0.00154	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—thymus cancer	6.25e-05	0.00142	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—thymus cancer	6.23e-05	0.00142	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—thymus cancer	5.8e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—thymus cancer	5.73e-05	0.0013	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—thymus cancer	5.57e-05	0.00127	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—thymus cancer	5.55e-05	0.00126	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—thymus cancer	4.6e-05	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—thymus cancer	4.03e-05	0.000916	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—thymus cancer	3.89e-05	0.000883	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—thymus cancer	3.38e-05	0.000768	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—thymus cancer	3.12e-05	0.000709	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—thymus cancer	2.59e-05	0.000588	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—thymus cancer	2.19e-05	0.000496	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—thymus cancer	6.93e-06	0.000157	CbGpPWpGaD
